Macrophage Pharma has an expanding pipeline of new chemical entity (NCE) assets leveraging the ESM™ targeting platform to shape macrophage biology in multiple diseases including cancer, liver injury, fibrosis and other autoimmune diseases where macrophages are centrally involved.

Product Discovery Hit to Lead Pre-clinical Phase 1 Phase 2
ESM™ p38MAPK inhibitor
Cancer and inflammation
ESM™-P13K/mTOR inhibitor
Cancer and fibrosis
ESM™-inflammasome inhibitor
Liver disease NAFLD/NASH
ESM™ immune kinase inhibitor